Actively Recruiting
Amyloid PET in Patients With Mild Cognitive Impairment and Early Dementia
Led by University Hospital, Ghent · Updated on 2024-05-20
50
Participants Needed
1
Research Sites
103 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The National Institute on Aging together with the Alzheimer's Association (NIA-AA) recently proposed the ATN classification which is based upon the pathological processes present in Alzheimer's disease (amyloid, tau and neurodegeneration). The amyloid and tau status can be defined using cerebrospinal fluid analysis but also non-invasively using an amyloid or tau PET scan. The N status can be defined using an \[18F\]-FDG PET scan which is in Belgium part of standard of care. Recently, it has been demonstrated, using different amyloid PET tracers, that early-frame amyloid scans can be a surrogate for \[18F\]-FDG PET scan.
CONDITIONS
Official Title
Amyloid PET in Patients With Mild Cognitive Impairment and Early Dementia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with mild cognitive impairment or early stage dementia who have a MRI and [18F]FDG PET/CT scan as part of routine clinical work-up
You will not qualify if you...
- Patient is not able to understand the study Patient is not able to lie still in the scanner for at least 30 minutes Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Van Weehaeghe D
Ghent, Belgium, 9000
Actively Recruiting
Research Team
V
Van Weehaeghe Donatienne
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here